On April 5, This ‘X’ Pattern Changes Everything

It appeared before Ambrx Biopharma climbed 175%... before AMC soared over 1,000%... Now, it’s appearing in multiple stocks on a regular basis. Luke Lango believes he’s cracked the code. On April 5, he’s going to reveal everything – including a free X-pattern pick.

Wed, April 5 at 4:00PM ET

Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears

  • Several monkeypox stocks are rallying today, with some up as much as 50%.
  • There are worries that there will be a shortage of vaccines for the virus in the U.S.
  • In recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox.
monkeypox stocks - Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears

Source: angellodeco / Shutterstock.com

Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox.

Several related names rallied in pre-market trading today and are still up since the market opened this morning. SIGA (NASDAQ:SIGA) is climbing 6%, GeoVax Labs (NASDAQ:GOVX) is soaring 50% and Virax Biolabs (NASDAQ:VRAX) is jumping 45%.

Monkeypox Stocks and Shortage Concerns

The U.S. has obtained 1.1 million doses of the two-dose Jynneos vaccine, and 786,000 of those have been cleared by regulators. The only shot currently approved by the Food and Drug Administration (FDA) for preventing monkeypox, Jynneos, is produced by Denmark-based Bavarian Nordic (OTCMKTS:BVNRY). The jab was originally a smallpox vaccine, but it has been found to be 85% effective in protecting people from getting monkeypox.

The U.S. is slated to acquire about 2 million doses of the vaccine by the end of the year, but 3.2 million shots are needed to protect those who are at risk of contracting the disease.

In the middle of last week, 4,600 cases of monkeypox had been identified in the U.S., and the number of cases is believed to be doubling every 7.6 days.

The U.S. has more than 100 million doses of a separate vaccine for smallpox, known as ACAM2000, which is made by Emergent Biosolutions (NYSE:EBS). But ACAM2000 has a higher risk of side effects than Jynneos, according to the Centers for Disease Control and Prevention (CDC).

According to The Washington Post, “the virus has yet to be linked to a single confirmed U.S. death.”

On Saturday, New York City announced that monkeypox had become an emergency within its borders. A day earlier, New York state had also declared the illness an emergency, while San Francisco issued a similar announcement on Thursday.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Larry Ramer held no positions in any companies mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.

Article printed from InvestorPlace Media, https://investorplace.com/2022/08/monkeypox-stocks-govx-vrax-siga-rocket-on-vaccine-shortage-fears/.

©2023 InvestorPlace Media, LLC